Chimeric Antigen Receptor T-Cell Therapy

BIOLOGICAL15 trials

Sponsors

Stanford University, Fred Hutchinson Cancer Center, Federal Research Institute of Pediatric Hematology, Oncology and Immunology, City of Hope Medical Center, Jonsson Comprehensive Cancer Center

Conditions

Acute Lymphocytic Leukemia, PediatricB Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaBreast CancerCD19 PositiveCD20 PositiveChronic Graft Versus Host DiseaseDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation

Early Phase 1

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

RecruitingNCT05800405

City of Hope Medical CenterRecurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

Start: 2023-07-20End: 2027-01-04Target: 9Updated: 2026-02-04

Phase 1

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruitingNCT03233854

Stanford UniversityB Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease +1

Start: 2017-09-01End: 2035-09-01Updated: 2025-11-18

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

Active, not recruitingNCT03241940

Stanford UniversityB Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease +4

Start: 2017-10-20End: 2035-08-01Target: 33Updated: 2025-06-29

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Active, not recruitingNCT03277729

Fred Hutchinson Cancer CenterRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Recurrent Chronic Lymphocytic Leukemia +20

Start: 2017-12-05End: 2039-03-31Updated: 2026-01-05

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyAcute Lymphocytic Leukemia, Pediatric, B-cell Acute Lymphoblastic Leukemia

Start: 2018-05-14End: 2025-10-15Target: 18Updated: 2023-02-24

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Active, not recruitingNCT03696030

City of Hope Medical CenterBreast Cancer, HER2-positive Breast Cancer, Malignant Neoplasm +2

Start: 2018-08-31End: 2026-02-19Updated: 2025-04-13

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Active, not recruitingNCT04007029

Jonsson Comprehensive Cancer CenterCD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia +11

Start: 2019-10-04End: 2027-08-01Target: 24Updated: 2025-09-05

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

RecruitingNCT05052528

Mehrdad Abedi, MDRecurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

Start: 2021-09-17End: 2025-12-15Target: 36Updated: 2024-05-13

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

SuspendedNCT05993611

City of Hope Medical CenterChronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease

Start: 2024-02-19End: 2028-05-21Target: 27Updated: 2025-11-13

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

RecruitingNCT06815029

City of Hope Medical CenterRecurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma

Start: 2025-06-17End: 2030-10-11Target: 27Updated: 2025-06-26

Phase 2

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Active, not recruitingNCT05202782

Northwestern UniversityDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified +16

Start: 2022-03-21End: 2029-10-09Target: 24Updated: 2024-10-16

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

RecruitingNCT06104592

H. Lee Moffitt Cancer Center and Research InstituteLarge B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma

Start: 2023-11-08End: 2026-12-01Target: 27Updated: 2026-03-31

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

RecruitingNCT06784726

University of WashingtonRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma +9

Start: 2025-09-04End: 2033-04-11Target: 27Updated: 2026-03-13

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

RecruitingNCT06834373

Mayo ClinicLarge B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma +28

Start: 2025-04-02End: 2027-03-03Target: 41Updated: 2026-01-28

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

RecruitingNCT06854159

Joseph TuscanoRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma +1

Start: 2025-08-07End: 2029-04-30Target: 34Updated: 2025-09-29

Related Papers

Abstract LB-C001: Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma: Updated Results with Over Four Years Median Follow Up

Cancer Immunology Research2026-03-05

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Blood2025-11-03

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

Blood2025-11-03

Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL

Blood2024-11-052 citations

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Blood2024-11-051 citations

CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL

Blood2024-11-051 citations

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood2024-11-051 citations

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood2024-07-0519 citations

Abstract 6325: Lineage tracing defines responding CAR T cells in patients with B cell malignancies

Cancer Research2024-03-22

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Blood2023-11-023 citations

A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

Blood2023-11-022 citations

Abstract CT023: Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma

Cancer Research2023-04-141 citations

Abstract 1128: Lineage tracing of CAR T cells in patients with B cell malignancies

Cancer Research2023-04-042 citations

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Cancer Discovery2022-11-2386 citations

CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.

Journal of Clinical Oncology2022-06-0112 citations

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Nature Communications2021-12-1066 citations

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Blood2021-11-0511 citations

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.

2021-07-26438 citations

Abstract CT007: CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas

Cancer Research2021-07-012 citations

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

4 more papers not shown